You'll notice that -- unlike the others, Pfizer goes into far less detail about exactly what they are jaw-boning about. It is my opinion (expressed here, on and off for about 15 years) that, given how relatively high the company's spend on lobbying is every year -- that this below, barely meets the command of the statute, to describe, in reaonable detail, "a list of the specific issues upon which a lobbyist employed by the registrant engaged in lobbying activities, including, to the maximum extent practicable, a list of bill numbers and references to specific executive branch actions. . . ." at 2 USC § 1604 Section (b)(2)(A):
. . .[US House] Vaccine Coverage; Pediatric Immunization Schedule; Vaccine Injury Compensation Program; Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; H.R. 7837 - Most Favored Patient Act of 2026; Lyme Disease Issues; 340B Issues; Counterfeit Drugs; Inflation Reduction Act (IRA); Prescription Drug User Fee Act (PDUFA); Drug Pricing; PBM Reform; Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage; H.R. 5509 - Safe Step Act; S. 2903 - Safe Step Act; S. 3510 - Biosimilar Inspection Modernization Act of 2025. . . .
[US Senate] Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; Prescription Drug User Fee Act (PDUFA); 340B Issues; Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage; PBM Reform; Counterfeit Drugs; P.L. 117-169 - Inflation Reduction Act (IRA) of 2022; Drug Pricing; Medicare/Medicaid Issues. . . .
International Supply Chain; Market Access; Most Favored Nation Policies; Foreign Freeriding Issues; Non-Tariff Trade Barriers; Competiveness Issues; Trade Issues. . . .
Intellectual Property Protections. . . .
Onward, to a warm if cloudy Spring Friday morning -- Eli Lilly likely up next, before Noon. Smile. . . .
नमस्ते
No comments:
Post a Comment